While idiopathic pulmonary fibrosis (PF) is a devastating lung disease, the management of PF including effective monitoring of disease progression remains a challenge. Our previous study demonstrated that recombinant mouse SCGB3A2 exhibits anti-fibrotic activity in bleomycin-induced pulmonary fibrosis model mouse. We applied this mouse model in conjunction with the use of SCGB3A2 to introduce and validate a novel, fast, and ultrasensitive metalloproteinase (MMP) activatable optical probe, named MMP-P12, to noninvasively monitor pulmonary fibrosis (PF) progression and response to PF treatment. The MMP-P12 probe is a substrate for MMPs and contains a fluorescent dye and a quencher dye, which fluoresces only when the quencher dye is cleaved by MMPs. The use of MMP-P12 in PF model is based on the fact that MMPs such as MMP2 are thought to be highly expressed in fibrotic tissues. A bleomycin (BLM)-induced mouse PF model was subjected noninvasively to optical imaging at various time points after BLM treatment. The mouse PF model developed fibrosis during 21 days of the experimental period, and the progression of PF was well correlated with the stepwise increase of MMP2 expression as examined by quantitative RT-PCR and Western blot analysis on 7-, 14-, and 21-day post-BLM administration. On these days, MMP-activated fluorescence images were acquired in vivo and ex vivo. Signal quantification showed time dependent lung-specific incremental increases in fluorescence signals. As a treatment for PF, SCGB3A2 was administered intravenously daily for five days starting on day seven of BLM administration, which resulted in reduced MMP2 activity and reduction of PF. Importantly, the fluorescence signal that reflected MMP activity also decreased in intensity. In conclusion, MMPs may play an important role in PF development and the MMP-P12 probe could be a promising tool for PF detection, even at an early stage of the disease as well as an indicator of therapy response. The MMP-P12 may provide a promising tool for detection and/or assessment of PF progression.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Cai, Yan; Winn, Melissa E; Zehmer, John K et al. (2014) Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis. Am J Physiol Lung Cell Mol Physiol 306:L10-22
Miyano, Yuki; Tahara, Shigeyuki; Sakata, Ichiro et al. (2014) Regulation of LH/FSH expression by secretoglobin 3A2 in the mouse pituitary gland. Cell Tissue Res 356:253-60
Kurotani, Reiko; Kumaki, Nobue; Naizhen, Xu et al. (2011) Secretoglobin 3A2/uteroglobin-related protein 1 is a novel marker for pulmonary carcinoma in mice and humans. Lung Cancer 71:42-8
Yamada, Atsushi; Suzuki, Dai; Miyazono, Agasa et al. (2009) IFN-gamma down-regulates Secretoglobin 3A1 gene expression. Biochem Biophys Res Commun 379:964-8
Tomita, Takeshi; Yamada, Atsushi; Miyakoshi, Masaaki et al. (2009) Oncostatin M regulates secretoglobin 3A1 and 3A2 expression in a bidirectional manner. Am J Respir Cell Mol Biol 40:620-30
Tomita, Takeshi; Kimura, Shioko (2008) Regulation of mouse Scgb3a1 gene expression by NF-Y and association of CpG methylation with its tissue-specific expression. BMC Mol Biol 9:5
Kurotani, Reiko; Tomita, Takeshi; Yang, Qian et al. (2008) Role of secretoglobin 3A2 in lung development. Am J Respir Crit Care Med 178:389-98
Tachihara-Yoshikawa, Motoko; Ishida, Takashi; Watanabe, Kana et al. (2008) Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas. Fukushima J Med Sci 54:61-72
Tomita, Takeshi; Kido, Taketomo; Kurotani, Reiko et al. (2008) CAATT/enhancer-binding proteins alpha and delta interact with NKX2-1 to synergistically activate mouse secretoglobin 3A2 gene expression. J Biol Chem 283:25617-27
Inoue, Keiichi; Wang, Xintao; Saito, Junpei et al. (2008) Plasma UGRP1 levels associate with promoter G-112A polymorphism and the severity of asthma. Allergol Int 57:57-64